With 0.13 million shares changed hands, the volume of the stock remained heavier than its average volume of 78970.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $12.13 whereas the lowest price it dropped to was $11.46. The 52-week range on AARD shows that it touched its highest point at $19.58 and its lowest point at $4.88 during that stretch. It currently has a 1-year price target of $31.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AARD was up-trending over the past week, with a rise of 7.00%, but this was up by 15.82% over a month. A look at the trailing 12-month EPS for AARD yields -3.16 with Next year EPS estimates of -2.50. For the next quarter, that number is -0.65. This implies an EPS growth rate of 49.81% for this year and 3.09% for next year.
Float and Shares Shorts:
At present, 21.69 million AARD shares are outstanding with a float of 12.39 million shares on hand for trading. On 2025-05-30, short shares totaled 0.34 million, which was 158.00001 higher than short shares on 1745971200. In addition to Dr. Tien-Li Lee M.D. as the firm’s CEO, Secretary & Director, Dr. Bryan Jones Ph.D. serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 0.49490002 of AARD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, AARD reported revenue of $0.0 and operating income of -$10470000.0. The EBITDA in the recently reported quarter was -$10450000.0 and diluted EPS was -$0.71.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With AARD analysts setting a high price target of 50.0 and a low target of 20.0, the average target price over the next 12 months is 31.25. Based on these targets, AARD could surge 313.91% to reach the target high and rise by 65.56% to reach the target low. Reaching the average price target will result in a growth of 158.69% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.855 being high and -$2.855 being low. For AARD, this leads to a yearly average estimate of -$2.855.
